Consistent with the results from breast cancer patient-derived CTCs, we observed downregulation of focal adhesion, cell–matrix adhesion, and ECM components (Fig. 4K-L) as well as suppression of TEAD2 in CTC clusters relative to their primary tumor counterparts (Fig. 4M). The gene discussed is TEAD2; the disease is breast cancer.